Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine possible alterations in cardiac function in patients with Rheumatoid Arthritis and Ankylosing Spondylitis under anti-TNF therapy, without clinical heart disfunction at baseline, using highly sensitive non-invasive methods.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Sao Paulo
• Treatments: Adalimumab; Etanercept; Infliximab; Natriuretic Peptide, Brain; Tumor Necrosis Factor Inhibitors

Criteria

Inclusion Criteria:

• Diagnosis of Rheumatoid Arthritis eligible to receive TNF blockers

• Diagnosis of Ankylosing Spondylitis eligible to receive TNF blockers

Exclusion Criteria:

• Clinical heart failure

• Chagas'disease

• Stable or unstable angina

• Past history of myocardial infarct

• Systemic árterial hypertension (grade 3)

• Valvulopathy

• Chronic kidney disease